Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont. , April 16, 2025 /PRNewswire/ —

Full Year 2024 Revenue Growth of 28% Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital BELGRADE, MT / ACCESS

Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31% BELGRADE,

BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for

BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for

BELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leading global medical technology company focused on the treatment of

BELGRADE, MT / ACCESSWIRE / September 18, 2024 /) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical

Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT, May 15, 2024 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE

BELGRADE, Mont. , May 13, 2024 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the